News and Announcements
Drivemycar Signs Strategic Agreement With $1bn Vehicle Leasing Giant Orix
- Published February 28, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
- Strategic agreement signed with ORIX Australia Corporation Limited, part of the ORIX Group, the largest fleet management group in Asia Pacific
- Significantly improves DriveMyCar’s sales potential from corporate and private markets
- Increases supply of vehicles in key locations that are especially convenient for corporate renters
- Provides ORIX with new revenue stream and improves utilisation of vehicles.
Collaborate Corporation Limited (ASX:CL8 or the Company) is pleased to announce that its DriveMyCar business has signed a strategic agreement with ORIX Australia Corporation Limited (ORIX) for ORIX vehicles to be rented through the DriveMyCar platform to private and corporate rental customers. The first vehicles will be made available in Sydney in March 2017, with launches in Melbourne and Brisbane to follow shortly afterwards.
Under the agreement, DriveMyCar will manage marketing of the vehicles, rental bookings, payments and verification checks while ORIX will handover the vehicles from their conveniently located offices around Australia. With locations in key business centres in Macquarie Park in Sydney and Eagle Farm in Brisbane, the ORIX vehicles will appeal to corporate customers seeking convenient access to reasonably priced quality rental vehicles. DriveMyCar will specifically target corporate customers with a localised marketing campaign for the ORIX vehicles.
To view the full ASX Announcement, please click here.
Company Updates
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
Backed By Leading Investment Groups and Family Offices
